From protests to where in 2012?

A complicated bus-ride

Rio: not plus or minus, just 20

Climate lectures don't make lessons

Grow food anywhere

With innovative use of space, people in cities are reclaiming their right to safe food

Yale guide to fighting drug patent barriers

How human rights can be used to challenge oppressive intellectual property laws

Doha: inaction in the face of urgency

Connected events and difficult future

Deal won, stakes lost

Cancun deal shifts burden on developing countries not developed

Cipla's audacious move

Why generics maker Cipla has asked government to revoke Novartis patent on respiratory ailment drug

Gunning for green tech

US continues to target India over its intellectual property regime, especially in pharma, green tech sectors

Patent hypocrisies of US

American business lobbies are spreading falsehoods about India’s patent policies—and glossing over their double standards

The endgame at Cancun

Vitamin D complex

When sunlight falls on the skin, it forms an essential nutrient, vitamin D. For people in India, which has an average of 300 clear sunny days in …

Weather dice is loaded

How to rewrite the Durban script

Equity: the next frontier in climate talks

Not rebuilding for tomorrow

The Bhopal legacy: reworking corporate liability

The real pandemic

Control your food. It is your business

Power games at UN climate talks

Climate talks unfolded amid high drama. Developing countries protested inaction by developed countries, civil society organisations walked out, …

Clouds over solar

Wooing the judges, openly

There is conflict of interest as US patent owners schedule meetings with Indian judiciary and patent regulators

US pharma strikes back

Upset by the Supreme Court’s endorsement of India’s patent law, the American drug industry is lobbying with Obama to tighten the …